International breast cancer prevention study launches in the United States and Canada

es national and international trials of cancer therapy, including trials for new cancer drugs, cancer prevention and supportive care to improve quality of life for people with cancer. Since its inception, the NCIC CTG has enrolled more than 40,000 patients from Canada and around the world in over 300 clinical trials.

Pfizer, Inc. manufactures exemestane under the brand name Aromasin and is providing the drug for the trial.

Women looking for more information about the ExCel research study and participating study centers in their community can visit www.excelstudy.com or call toll-free:

  • In the U.S. 1-800-4-CANCER
  • In Canada 1 888 939-3333

    About Exemestane

    Exemestane (Aromasin) was approved in the United States late in 1999 for the treatment of advanced breast cancer in postmenopausal women whose tumors have stopped responding to tamoxifen. Exemestane is approved by the FDA and Health Canada and is marketed by Pfizer, Inc. as Aromasin. It is also approved for use in Europe, Japan, and South America. It is currently used for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

    Results of the Intergroup Exemestane Study, published in the New England Journal of Medicine, revealed that 32 percent fewer women had a recurrence in their breast cancer when they switched to exemestane after two to three years of tamoxifen compared to those who continued on tamoxifen for a total of five years, the current standard of care. Additionally, twice as many women receiving tamoxifen developed second (or new) breast cancers than those treated with exemestane.

    Unlike other aromatase inhibitors, exemestane is a steroidal aromatase inactivator, which means it selectively targets and irreversibly binds to the aromatase enzyme, which is required to produce estrogen. Without estrogen, breast can

  • Contact: Samantha Kaplan
    Edelman Public Relations

    Page: 1 2 3 4

    Related medicine news :

    1. National Academies advisory: May 2 Symposium on International Science Policy
    2. Awards & fellowships at the International & American Association for Dental Research General Session
    3. Lectures, keynoters, symposia highlight International Dental Research meeting
    4. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress
    5. International gathering of experts to share retinoblastoma breakthroughs
    6. International trial of two microbicides begins
    7. International gathering at UH examines top computer code
    8. International trial finds benefits of breast MRI in women at high risk
    9. International study provides culture-by-culture clues to family violence and abuse
    10. St. Jude scientist wins International Society of Experimental Hematology award
    11. International MRC trial finds a routine treatment for head injury may do more harm than good

    Post Your Comments:

    (Date:10/13/2017)... ... 2017 , ... The American Board of Family Medicine's (ABFM) Board of Directors ... Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in ... retirement at the end of 2018. Upon assuming the role of President and CEO ...
    (Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
    (Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
    (Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
    Breaking Medicine News(10 mins):
    (Date:10/11/2017)... CHICAGO , Oct. 11, 2017  Hill-Rom Holdings, ... its Aspen Surgical facility in Las Piedras, ... surgical scalpels and blades. ... confirmed that the facility sustained minor structural damage, temporary ... Hurricane Maria. Repairs have been completed, manufacturing operations have ...
    (Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
    (Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
    Breaking Medicine Technology:
    Cached News: